Asset
ASPARAGINASE ERWINIA CHRYSANTHEMI
Jazz Pharmaceuticals plc Common Stock (Ireland)
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01643408 | phase2 | completed | 2012-11-01 | 2013-08-01 | Jazz Pharmaceuticals | A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy |
| NCT02150928 | phase2 | withdrawn | 2014-05-01 | 2015-06-01 | Jazz Pharmaceuticals | An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase) |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| BLA 125359 | BLA | Jazz Pharmaceuticals, Inc. |
Marketed products (1)
- Erwinaze